Trial reportPediatrics2025
Feasibility and Acceptability of Recommending HPV Vaccine at Ages 9-10 Years.
Trial report in Pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years.Pediatrics · 2026Trial
- Article
- Healthcare provider perspectives on HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- How Immunization Information Systems Inform Age-Based HPV Vaccination Recommendations in the United States: A Mixed-Methods Study.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThe human papillomavirus (HPV) vaccine is routinely recommended at ages 11-12 and may be given as early as ages 9-10 years. We assessed primary care clinician and staff experiences with feasibility and acceptability of initiating at ages 9-10 years.
methodsThis explanatory sequential mixed-methods study was part of an ongoing randomized trial comparing initiation at ages 9-10 years (intervention) vs 11-12 years (control) across 17 practices in Colorado (CO; 9 intervention) and 16 practices in California (CA; 8 intervention). We surveyed intervention practice clinicians at 1 month after study initiation and conducted semi-structured interviews at 3 months after study initiation. We used descriptive statistics to analyze surveys and content analysis for interviews.
results66 (92%) CO and 39 (87%) CA clinicians completed 1-month surveys; 59 (90%) in CO and 30 (77%) in CA were routinely initiating vaccines at age 9 or 10 years. Most reported that vaccination at ages 9-10 years was not burdensome, and issues were largely unchanged, including parental concerns and discussion times. Interviewees (18 clinicians, 17 staff) reported that many parents seemed receptive to discussing HPV vaccination at ages 9-10 years, pushback often stemmed from child expectations for a vaccine-free visit at age 9 years rather than vaccine concerns, and discussions at ages 9-10 years were shorter because sexual activity was not perceived as salient. Many preferred the option to space out vaccines by administering a single vaccine at age 9 years and fewer at age 11 years.
conclusionClinicians and staff perceived recommending the HPV vaccine at ages 9-10 years as feasible for clinicians, compatible with workflows, and generally acceptable to parents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.